Word: allergan
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...tuck trend has been a boon to some medical-supply companies. In the third quarter, Allergan Inc., which sells breast implants, Botox and other wrinkle-fighting products, said higher-than-expected Botox sales helped the company post an 8% earnings increase and exceed Wall Street's expectations. The company, predictably, opposes...
...quest for more luscious lashes has even reached the pharmaceutical industry. In January, Allergan, the company that made Botox a household name, introduced Latisse, the first FDA-approved prescription drug to aid growth of longer, fuller lashes. Suggested retail price: $120 for a 30-day supply. But stop using the pricey solution and lashes will eventually shrink to their original size. At least there will always be falsies to fall back...
When 1970s Olympic heroes--and mustachioed ones at that--get work done, it would seem to mark social acceptability among guys. Spitz, though, is a spokesman for Allergan, the company that makes Botox and has started to market directly to men via its website. Sure, Spitz first considered getting the world's most common cosmetic procedure after a friend, former Olympic gymnast Nadia Comaneci, told him that the wrinkles between his eyes made him look old and overly serious, but he got a whole lot more interested when Allergan started paying...
...moment, though, Allergan has the competitive edge. Juvéderm will roll out in January. Medicis' Perlane won't be available until the middle of next year; Reloxin isn't expected until early 2008. Shacknai isn't too worried. He expects that market leader Restylane will hold on to its share of the filler segment and its near 90% profit margins. "We're the leading filler and have lots of pioneering products coming to market," he says. "Eventually, we will be able to meet every need for filling the face...
...will Allergan. After buying up Inamed, minus Reloxin, it formed a separate medical-aesthetics division. Part of its mission, according to its head, Robert Grant: to build "a total facial-rejuvenation portfolio" that can capitalize on Allergan's Botox-driven market reach. "This is an opportunity to create a new category which will have legs not just for the next decade but for the next 100 years," he says...